Literature DB >> 16278861

Lipoprotein-associated phospholipase A2 is associated with risk of dementia.

Marieke van Oijen1, Irene M van der Meer, Albert Hofman, Jacqueline C M Witteman, Peter J Koudstaal, Monique M B Breteler.   

Abstract

OBJECTIVE: High levels of the inflammatory marker lipoprotein-associated phospholipase A2 (Lp-PLA2) have been proposed to be a predictor of coronary heart disease and stroke. Because both inflammation and vascular disease are associated with dementia, the objective of the present study was to examine the association between Lp-PLA2 and the risk of dementia.
METHODS: Within the Rotterdam Study, a population-based prospective cohort study, we performed a case-cohort study. Of the 6,713 participants at risk for dementia, a random sample of 1,742 individuals was drawn. During follow-up (mean, 5.7 years), 302 incident dementia cases were identified. Cox proportional hazard models were used to estimate the association of Lp-PLA2 and dementia.
RESULTS: We found that subjects with higher levels of Lp-PLA2 had an increased risk of dementia. Compared with the first quartile of Lp-PLA2, age- and sex-adjusted hazard ratios (HRs; 95% confidence interval [CI]) for dementia for the second, third, and fourth quartiles were 1.19 (0.78-1.81), 1.15 (0.74-1.79), and 1.56 (1.03-2.37), respectively (p value for trend 0.04). Additional adjustment for cardiovascular and inflammatory factors did not change the estimates.
INTERPRETATION: This is the first study to our knowledge that shows that Lp-PLA2 is associated with the risk of dementia independent of cardiovascular and inflammatory factors and provides evidence for a potential role of Lp-PLA2 in identifying subjects at risk for dementia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16278861     DOI: 10.1002/ana.20721

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  16 in total

1.  Disease risk factors identified through shared genetic architecture and electronic medical records.

Authors:  Li Li; David J Ruau; Chirag J Patel; Susan C Weber; Rong Chen; Nicholas P Tatonetti; Joel T Dudley; Atul J Butte
Journal:  Sci Transl Med       Date:  2014-04-30       Impact factor: 17.956

2.  Lipoprotein-associated phospholipase A2 and risk of dementia in the Cardiovascular Health Study.

Authors:  Annette L Fitzpatrick; Michael C Irizarry; Mary Cushman; Nancy S Jenny; Gloria C Chi; Carol Koro
Journal:  Atherosclerosis       Date:  2014-05-22       Impact factor: 5.162

3.  Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and alzheimer disease: results from the Framingham Heart Study.

Authors:  Thomas M van Himbergen; Alexa S Beiser; Masumi Ai; Sudha Seshadri; Seiko Otokozawa; Rhoda Au; Nuntakorn Thongtang; Philip A Wolf; Ernst J Schaefer
Journal:  Arch Neurol       Date:  2012-05

4.  Inflammatory biomarkers of vascular risk as correlates of leukoariosis.

Authors:  Clinton B Wright; Yeseon Moon; Myunghee C Paik; Truman R Brown; LeRoy Rabbani; Mitsuhiro Yoshita; Charles DeCarli; Ralph Sacco; Mitchell S V Elkind
Journal:  Stroke       Date:  2009-08-20       Impact factor: 7.914

5.  ApoB, small-dense LDL-C, Lp(a), LpPLA2 activity, and cognitive change.

Authors:  Yashashwi Pokharel; Farah Mouhanna; Vijay Nambi; Salim S Virani; Ron Hoogeveen; Alvaro Alonso; Gerardo Heiss; Josef Coresh; Thomas Mosley; Rebecca F Gottesman; Christie M Ballantyne; Melinda C Power
Journal:  Neurology       Date:  2019-05-01       Impact factor: 9.910

Review 6.  Cardiovascular risk factors and future risk of Alzheimer's disease.

Authors:  Renée F A G de Bruijn; M Arfan Ikram
Journal:  BMC Med       Date:  2014-11-11       Impact factor: 8.775

7.  Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease.

Authors:  Rachelle S Doody; Jasenka Demirovic; Christie M Ballantyne; Wenyaw Chan; Robert Barber; Suzanne Powell; Valory Pavlik
Journal:  Alzheimers Dement (Amst)       Date:  2015-09-21

8.  Lipoprotein-associated Phospholipase A2 Is Associated with Risk of Mild Cognitive Impairment in Chinese Patients with Type 2 Diabetes.

Authors:  Rongrong Cai; Rong Huang; Jing Han; Haixia Sun; Jie Sun; Wenqing Xia; Sai Tian; Xue Dong; Yanjue Shen; Shaohua Wang
Journal:  Sci Rep       Date:  2017-09-26       Impact factor: 4.379

9.  Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study.

Authors:  Julie E Davidson; Andrew Lockhart; Leslie Amos; Heide A Stirnadel-Farrant; Vincent Mooser; Marc Sollberger; Axel Regeniter; Andreas U Monsch; Michael C Irizarry
Journal:  Alzheimers Res Ther       Date:  2012-12-07       Impact factor: 6.982

10.  Higher Levels of Lipoprotein Associated Phospholipase A2 is associated with Increased Prevalence of Cognitive Impairment: the APAC Study.

Authors:  Ruixuan Jiang; Shengyun Chen; Yuan Shen; Jianwei Wu; Shuohua Chen; Anxin Wang; Shouling Wu; Xingquan Zhao
Journal:  Sci Rep       Date:  2016-09-09       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.